A small clinical trial testing Agios Pharmaceuticals’ oral therapy candidate tebapivat against a placebo for easing symptoms in people with sickle cell disease (SCD) has completed enrollment, the company announced. Agios expects to report early results from the Phase 2 trial later this year, according to a…